Switchable photooxygenation catalysts that sense higher-order amyloid structures

Area of Science:

• Biochemistry
• Chemical Biology
• Molecular Biology

Background:

• Protein misfolding into amyloid structures is linked to various debilitating diseases.
• Selective degradation of pathogenic amyloid forms while preserving functional protein is a significant therapeutic challenge.

Purpose of the Study:

• To develop artificial catalysts capable of selectively targeting and degrading amyloid protein aggregates.
• To investigate the potential of these catalysts in treating amyloid-related pathologies.

Main Methods:

• Design and synthesis of target-state-dependent photooxygenation catalysts.
• Testing catalyst activity against amyloid-beta (Aβ) 1-42 and other amyloidogenic proteins (amylin, insulin, β2-microglobulin, transthyretin, α-synuclein).
• Evaluation of catalyst selectivity for cross-β-sheet structures characteristic of amyloid aggregates.
• Assessment of catalyst impact on non-amyloidogenic protein functions.
• In vitro studies to evaluate the attenuation of Aβ pathogenicity using modified catalysts.

Main Results:

• Developed photooxygenation catalysts active exclusively when bound to amyloid cross-β-sheet structures.
• Demonstrated selective oxygenation of amyloid-beta (Aβ) 1-42 aggregates in the presence of non-amyloid proteins.
• Showed that photooxygenation with an Aβ-binding peptide-conjugated catalyst reduced Aβ pathogenicity in cellular models.
• Confirmed the general applicability of selective photooxygenation to diverse amyloidogenic proteins, preserving their functional states.
• Established the first artificial catalyst with reversible, structure-dependent activation for protein aggregation states.

Conclusions:

• Novel photooxygenation catalysts provide a highly selective method for targeting and degrading pathogenic amyloid structures.
• This approach preserves the biological function of non-aggregated proteins, offering a promising therapeutic strategy.
• The developed catalysts represent a significant advancement in the field of amyloid disease treatment and protein aggregation research.